All three isoforms of transforming growth factors /3 (TGF-j1, TGF-382, and TGF-f3) are secreted as latent complexes and activated extracellularly, leading to the release of the mature cytokines from their noncovalently associated proregions, also known as latency-associated peptides (LAPs). The LAP region of TGF-p1 was expressed in a baculovirus expression system and purified to homogeneity. In Latent forms of TGF-3 purified from platelets and secreted by a number of cell types are high molecular weight complexes (5, 6) in which homodimeric mature TGF-3 is noncovalently associated with a dimer of its proregion, which itself can be disulfide-bonded to structurally and genetically unrelated latent TGF-3 binding proteins (7-10). In contrast, recombinant cell systems and certain cell types secrete a "small latent complex" consisting only of mature TGF-P, and its proregion (11-13). The proregion of TGF-31 [aa (14)], when independently expressed, associates noncovalently with mature TGF-3, inactivating its biological activities in vitro (15). Therefore, latency of TGF-P3 is a function conferred by its proregion, which is also termed latency-associated peptide.
The transforming growth factors 13 (TGF-3) are multifunctional cytokines with diverse effects on cell growth, differentiation, and function (1) . Experiments in animal model systems and transgenic mice, as well as studies of human diseases, have implicated TGF-3 in the regulation of important physiological and pathophysiological processes (2) (3) (4) .
Latent forms of TGF-3 purified from platelets and secreted by a number of cell types are high molecular weight complexes (5, 6) in which homodimeric mature TGF-3 is noncovalently associated with a dimer of its proregion, which itself can be disulfide-bonded to structurally and genetically unrelated latent TGF-3 binding proteins (7) (8) (9) (10) . In contrast, recombinant cell systems and certain cell types secrete a "small latent complex" consisting only of mature TGF-P, and its proregion (11) (12) (13) . The proregion of TGF-31 [aa (14) ], when independently expressed, associates noncovalently with mature TGF-3, inactivating its biological activities in vitro (15) . Therefore, latency of TGF-P3 is a function conferred by its proregion, which is also termed latency-associated peptide.
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Before TGF-f3 can exert its biological effects, latent complexes must be activated, presumably resulting in the release of mature TGF-3 (16) (17) (18) (19) . The structural changes of latencyassociated peptide required for release of active TGF-f3 and its fate after completion of the activation process are not known. Although certain types of in vitro activation are reversible (12) , it is not known whether the intact proregion and active TGF-3 can reassociate in vivo.
Elevated endogenous TGF-3 levels in diseased organs have been associated with the pathogenesis of fibrosis in experimental animal models and human diseases (4) , and elevated circulating TGF-31 is associated with the development of conditions characterized by fibrosis in liver and lungs in humans 120). Approaches to prevent matrix accumulation in experimental animal models using systemic antagonists of TGF-B have been promising (21) (22) (23) (24) . Thus, decreasing the activity of TGF-31 has enormous clinical potential in conditions with excessive scarring.
Liver regeneration following partial hepatectomy is a wellcharacterized model system for evaluating the effects of growth factors on hepatocellular proliferation in vivo (25) (26) (27) . Intravenously administered active TGF-B reversibly inhibits the early synchronized proliferative wave after partial hepatectomy in rats and mice (28, 29 above, except NaCI concentration of 1 x) and incubated at 4°C overnight with 3 plI of anti-human LAP antibody, followed by procedures as described above. All samples were eluted by boiling for 3 min in sample buffer and run on 4-12% SDS/ PAGE in parallel with native 125I-labeled LAP. Gels were dried and exposed to autoradiography.
Liver Regeneration After Partial Hepatectomy. The Alb/ TGF-f1 transgenic mice were generated in a (C57BL/6J x CBA) F1 genetic background as described (30) . Control (Fig. 1C) . LAP also antagonized the induction of fibronectin in MvlLu cells resulting from exogenously added TGF-31 (Fig. 1D, lane 3) , as well as from autocrine TGF-ps (Fig. 1D, lane 4) (Fig. 2B) . Therefore, the tissue distribution of 125I-labeled LAP closely resembles that observed for the reconstituted small latent complex containing 125I-labeled TGF-B1 injected intravenously in rats, and is substantially different from the tissue distribution of 25I-labeled TGF-/31 (40, 41) . In all organs examined except for the spleen, there was a consis- tent increase of radioactivity between 10 min and 120 min after injection, indicating a persistent release of injected radioactivity from the peritoneum (Fig. 2 A and B) . To determine whether 125I-labeled LAP recovered from tissues was intact, a polyclonal anti-human LAP antiserum was used to detect 125I-labeled LAP in liver homogenates prepared 30 min after injection. As shown in Fig. 2C Fig. 2 ), these findings suggest that 125I-labeled LAP is slowly absorbed from the peritoneal cavity into the portal and systemic circulation. This prohibits determination of plasma half life and rates of degradation of 25I-labeled LAP within the examined time frame. Immunoprecipitations of 25I-labeled LAP from plasma using polyclonal anti-LAP antiserum showed that the absorbed 125I-labeled LAP remained intact (Fig. 2C, lanes 1-4) . Furthermore (42, 43) . In Alb/TGF-31 transgenic mice with high levels of biologically active TGF-31 expressed in the liver, the early proliferative response measured at 36 h after partial hepatectomy by nuclear BrdUrd labeling index was 5-fold lower when compared with nontransgenic control mice (V.M.F., et al., unpublished work). We hypothesized that neutralization of TGF-B1 activity by LAP should result in a restoration of the normal early proliferative response after partial hepatectomy in Alb/TGF-B1 mice. The levels of TGF-31 protein as detected immunologically by the anti-LC(1-30-1) antibody (44) were consistently elevated in 8-week-old male Alb/TGF-B1 mice, when compared with male age-matched nontransgenic control mice (30) . Such Alb/TGF-B1 and control mice underwent a two-thirds partial hepatectomy, followed immediately by insertion of osmotic minipumps with or without LAP into the abdominal cavity. The rate of DNA synthesis as measured by nuclear BrdUrd labeling was 4.7-fold lower in Alb/TGF-B1 transgenic hepatectomized mice treated with PBS (1.0% ± 0.3%) when compared with hepatectomized nontransgenic control mice treated with PBS (4.7% ± 1.7%). In contrast, LAP treatment of Alb/TGF-B1 mice resulted in a nearly complete restoration of the early proliferative response (4.5% ± 1.7%) ( Fig. 3D ; see Fig. 3A -C for typical BrdUrd staining). This effect of LAP was dose-dependent, as it was only observed at a total dose of 64 ,tg. The labeling index in Alb/TGF-B1 mice treated with either 16 ,ug or 4 ptg of LAP was 0.4% ± 0.2% and 0.7% ± 0.3%, respectively, and not significantly different from that of Alb/ TGF-/31 mice treated with PBS (Fig. 3D) (30) . Second, previous in vitro observations suggested that LAP might target latent TGF-B complexes to cell surface receptors, such as the mannose-6-phosphate/insulin-like growth factor receptor, that have been implied in activation of latent TGF-3 in vitro (52) (53) (54) ; thus, LAP could potentially contribute to enhanced TGF-p activity. However, we observed inhibition of TGF-B1 activity suggesting that the in vivo reconstituted latent complex is not targeted to activation sites by LAP. Furthermore, the question whether reconstituted latent TGF-, in vivo is subject to previously described in vitro mechanisms of activation remains unanswered (16) (17) (18) 55) . It is possible that such mechanisms apply to reconstituted latent TGF-3, but that they cannot overcome the effects of pharmacological doses of LAP.
In situ differentiation of active TGF-p from latent TGF-P has not been possible until recently, when methods for selective detection and quantitation of activated TGF-B in situ have been developed (56, 57). It should soon be possible to define localization and levels of active TGF-( in situ in experimental animal models and human diseases. This will greatly facilitate in vivo investigation of inhibitors of TGF-3 with therapeutical potential.
Use of antagonists of TGF-3 may form the basis of important novel approaches in the future for the treatment of a large spectrum of serious chronic conditions in which excessive TGF-P action appears to be responsible for tissue damage caused by scarring (4, 58) . Indeed, in previous studies, antiserum to TGF-B or the proteoglycan, decorin, have been shown to protect against scarring in experimental skin lesions and kidney disease (22, 59) . LAP has excellent potential to become a potent and specific inhibitor of TGF-/3 for the prevention of fibrotic conditions. In this context, it will be important to examine whether the promising short term activity of LAP, as shown in the present study, can be sustained in more chronic disease models.
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